The US Food and Drug Administration has allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorised test for use with flow cytometry to aid in the detection of several leukaemias and lymphomas, including chronic leukaemia,...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2uVaGHh
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Objective Outpatient parenteral antimicrobial therapy (OPAT) provides opportunities for improved cost savings, but in the UK, implementation...
-
Caring for Patients with Physical Disabilities: Assessment of an Innovative Spinal Cord Injury Session that Addresses an Educational Gap Des...
-
Geriatric trauma: A population-based study Saint Shiou-Sheng Chen, Li-Chien Chien Formosan Journal of Surgery 2019 52(2):39-44 Background: G...
-
World Community; and Remarks on our Own Behalf Models of Anticipation Within the Responsible Research and Innovation Framework: the Two RRI ...
-
Ocular Vestibular Evoked Myogenic Potentials: Where Are We Now? Objective: Over the last decade, ocular vestibular evoked myogenic potential...
-
Abstract Objective To study the effects of Astragalus polysaccharide (APS), the primary effective component of the Chinese herb medicine A...
-
http://orl-agios.blogspot.com/2017/06/the-preclinical-anticancer-effect-of.html Flavonoids present in foods were considered non-absorbable b...
-
Abstract Objective To evaluate Chinese medicine (CM) formula Bazheng Powder (八正散) as an alternative therapeutic option for female patients...
-
Abstract Eslicarbazepine acetate is a new anti-epileptic drug belonging to the dibenzazepine carboxamide family that is currently approved ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου